Significance of Platelet-Derived Microparticles and Activated Platelets in Diabetic Nephropathy

We measured levels of platelet-derived microparticles (PMP), which have coagulative activity and are produced by platelet activation or physical stimulation, and CD62P/CD63-positive platelets in patients with diabetes mellitus to determine their clinical significance and effects on complications of diabetes including diabetic nephropathy. We also compared these levels before and after administration of the antiplatelet drug cilostazol. Plasma PMP and CD62P/CD63-positive platelet levels were significantly higher in patients with diabetes mellitus than normal controls. CD62P-positive platelet levels were significantly higher in patients with nephropathy than in patients without complications. After administration of cilostazol, PMP and CD62P/CD63-positive platelet levels were significantly decreased. The increases in platelet activity and its related procoagulant activity appear to account in part for the hypercoagulability observed in diabetes mellitus. Our findings suggest that activated platelets might play a role in the development of diabetic nephropathy. Furthermore, antiplatelet therapy with cilostazol for diabetic patients may be useful as antithrombin therapy including antiplatelet therapy, since it suppresses the production of intrinsic coagulants produced by platelet activation.

[1]  P. Vague,et al.  Red Cell Deformability, Platelet Aggregation, and Insulin Action , 1983, Diabetes.

[2]  P. Winocour.  Platelet Abnormalities in Diabetes Mellitus , 1992, Diabetes.

[3]  W. Clark,et al.  Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. , 1985, Hybridoma.

[4]  J. Mustard,et al.  The role of platelets in the development and complications of atherosclerosis. , 1986, Seminars in hematology.

[5]  J. V. van Oosterhout,et al.  Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. , 1987, Blood.

[6]  J. Sixma,et al.  Diabetes mellitus, vascular disease and thrombosis. , 1986, Clinics in haematology.

[7]  T. Iwasaka,et al.  Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease , 1996, European journal of clinical investigation.

[8]  M. Gawaz,et al.  Platelet-leukocyte aggregation during hemodialysis. , 1994, Kidney international.

[9]  Yasuo Ikeda,et al.  Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. , 1997, Life sciences.

[10]  S. Nomura,et al.  Differences between platelet and microparticle glycoprotein IIb/IIIa. , 1992, Cytometry.

[11]  P. Gaffney,et al.  Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. , 1987, Thrombosis research.

[12]  T. Wascher,et al.  Exposure To Elevated D-Glucose Concentrations Modulates Vascular Endothelial Cell Vasodilatory Response , 1993, Diabetes.

[13]  F. Gries,et al.  Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. , 1990, Cytometry.

[14]  V. Horejsi,et al.  Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63 , 1991, FEBS letters.

[15]  S. Nomura,et al.  Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. , 1995, Atherosclerosis.

[16]  R. Wada,et al.  Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. , 1997, Journal of diabetes and its complications.

[17]  J. Tuomilehto,et al.  International Comparisons of IDDM Mortality: Clues to Prevention and the Role of Diabetes Care , 1992, Diabetes Care.

[18]  H. Makino,et al.  Soluble P-Selectin Is Released from Activated Platelets in vivo during Hemodialysis , 1998, Nephron.

[19]  M. Nakajima,et al.  Detection of Activated Plateletsin Urine by Double Immunofluorescence in Children with IgA Nephropat hy , 1998, Nephron.

[20]  W. Hsueh,et al.  Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. , 1993, The American journal of cardiology.

[21]  Y. Komiyama,et al.  Effect of a New Monoclonal Anti-Glycoprotein IX Antibody, KMP-9, on High Shear-Induced Platelet Aggregation , 1997, Thrombosis and Haemostasis.

[22]  Packham Ma,et al.  The role of platelets in the development and complications of atherosclerosis. , 1986, Seminars in hematology.

[23]  Y. Komiyama,et al.  Amyloid β-Protein Precursor-Rich Platelet Microparticles in Thrombotic Disease , 1994, Thrombosis and Haemostasis.

[24]  S. Nomura,et al.  Influence of platelet-derived microparticles on coagulation in a lung cancer patient receiving chemotherapy. , 1993, Chest.

[25]  P. Halushka,et al.  PLATELET FUNCTION IN DIABETES MELLITUS , 1980, British journal of haematology.

[26]  C. Bjerkelund.  Diabetic Renal Disease. , 2009 .

[27]  H. Furukawa,et al.  Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. , 1992, Arzneimittel-Forschung.

[28]  M. Nishikawa,et al.  Significance of platelet-derived microparticles in uremia. , 1993, Nephron.

[29]  C. Venturini,et al.  Thrombin Induces Platelet Adhesion to Endothelial Cells , 1992, Seminars in thrombosis and hemostasis.

[30]  F. Gries,et al.  Large Platelets Circulate in an Activated State in Diabetes Mellitus , 1991, Seminars in thrombosis and hemostasis.

[31]  F. Gries,et al.  Platelets in Diabetes: The Role in the Hemostatic Regulation in Atherosclerosis , 1993, Seminars in thrombosis and hemostasis.

[32]  Y Komiyama,et al.  High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. , 1996, Blood.

[33]  M. Nakajima,et al.  Detection of activated platelets in urine by double immunofluorescence in children with IgA nephropathy. , 1998, Nephron.

[34]  M. Nishikawa,et al.  Analysis of platelet abnormalities in uremia with and without Glanzmann's thrombasthenia. , 1994, Nephron.

[35]  R. Taylor,et al.  The biochemistry of diabetes. , 1988, The Biochemical journal.

[36]  F. Nuttall,et al.  Veterans Administration Cooperative Study on Antiplatelet Agents in Diabetic Patients After Amputation for Gangrene: II. Effects of Aspirin and Dipyridamole on Atherosclerotic Vascular Disease Rates , 1986, Diabetes Care.

[37]  Tanaka Toshio,et al.  Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography , 1984 .

[38]  C. Esmon,et al.  Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. , 1989, The Journal of biological chemistry.

[39]  Banga Jd,et al.  Diabetes mellitus, vascular disease and thrombosis. , 1986 .

[40]  P. Sims,et al.  Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. , 1988, The Journal of biological chemistry.

[41]  K. Bauer,et al.  The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. , 1987, Blood.

[42]  K. Wakasa,et al.  Renal Dysfunction Worsened by Superimposition of IgA Glomerulonephritis in a Patient with Overt Diabetic Nephropathy , 1998, Nephron.

[43]  C. Abrams,et al.  Direct detection of activated platelets and platelet-derived microparticles in humans. , 1990, Blood.